Infant Bacterial Therapeutics AB (publ) (IBT-B.ST)

87.80 +0.40 (+0.46%) At close: 05:22PM CEST

Infant Bacterial Therapeutics AB (publ)

Bryggargatan 10
Stockholm 111 21
Sweden
46 7 62 19 37 38
https://www.ibtherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 8

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Staffan Stromberg Ph.D.	Chief Executive Officer	5.33M	N/A	1967
Ms. Maria Ekdahl	Chief Financial Officer	N/A	N/A	1973
Mr. Anders Kronström M.B.A., M.S.	Chief Operating Officer	500k	N/A	1967
Dr. Thomas J. Schnitzer M.D., Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Mr. Sanjiv Sharma M.B.A.	Head of Medical Affairs	N/A	N/A	1957
Prof. Jonas Rastad M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1950

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was incorporated in 2011 and is based in Stockholm, Sweden.

Corporate Governance

Infant Bacterial Therapeutics AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.